De Witte Ridder schreef op 14 november 2016 14:30:
Recently RUCONEST demonstrated very positive data for prophylaxis (prevention) of acute attacks of HAE in patients with HAE. If approved for this indication, RUCONEST® will have access to this additional market. RUCONEST® therefore,
has the potential to be the only recombinant C1 esterase inhibitor product approved to target both the acute market (worth approximately $845 million) and the HAE prophylaxis market (separately worth approximately $700 million).